PMID- 31080770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 8
IP  - 2
DP  - 2019 Apr
TI  - Transplant immunosuppressive drugs in urology.
PG  - 109-117
LID - 10.21037/tau.2018.07.12 [doi]
AB  - Immunosuppressive drugs are used in renal transplantation to prevent and treat 
      rejection and their use has traditionally been limited to urologists trained in 
      transplant surgery. However, there are other urologic conditions for which these 
      drugs have proven efficacy. Since transplant surgery has become a small niche 
      subspecialty within urology, most urologists are unfamiliar and uncomfortable 
      with their use. This review will focus on the use of Cyclosporine (CyA), 
      mycophenolate mofetil (MMF), and mammalian target of rapamycin (mTOR) inhibitors 
      in urology outside of solid organ transplant. This includes the treatment of 
      interstitial cystitis/bladder pain syndrome (IC/BPS) with CyA as well as the role 
      of CyA in eosinophilic cystitis (EC) and the treatment of retroperitoneal 
      fibrosis (RF) with MMF. Also included is the utilization of mTOR inhibitors in 
      both advanced renal cell carcinoma (RCC) and in patients with tuberous sclerosis 
      complex (TSC) associated angiomyolipoma (AML). Available clinical data on mTOR 
      inhibition in autosomal dominant polycystic kidney disease (ADPKD) is also 
      briefly presented. Specific attention is given to the indications for each agent, 
      the available evidence surrounding their use, and the most common adverse events 
      (AEs) and their subsequent management.
FAU - Crane, Alice
AU  - Crane A
AD  - Glickman Urological and Kidney Institute, Department of Urology, Cleveland 
      Clinic, Cleveland, OH, USA.
FAU - Eltemamy, Mohamed
AU  - Eltemamy M
AD  - Glickman Urological and Kidney Institute, Department of Urology, Cleveland 
      Clinic, Cleveland, OH, USA.
FAU - Shoskes, Daniel
AU  - Shoskes D
AD  - Glickman Urological and Kidney Institute, Department of Urology, Cleveland 
      Clinic, Cleveland, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC6503232
OTO - NOTNLM
OT  - Immunosuppression
OT  - cyclosporine (CyA)
OT  - interstitial cystitis (IC)
OT  - kidney cancer
OT  - mammalian target of rapamycin inhibitor (mTOR inhibitor)
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2019/05/14 06:00
MHDA- 2019/05/14 06:01
PMCR- 2019/04/01
CRDT- 2019/05/14 06:00
PHST- 2019/05/14 06:00 [entrez]
PHST- 2019/05/14 06:00 [pubmed]
PHST- 2019/05/14 06:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - tau-08-02-109 [pii]
AID - 10.21037/tau.2018.07.12 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2019 Apr;8(2):109-117. doi: 10.21037/tau.2018.07.12.